article Open AccessTop 1% cited
Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand
The Journal of Infectious Diseases · 2006 · Vol. 194(12) · pp. 1661–1671
Punnee Pitisuttithum✉(Mahidol University)Peter B. Gilbert(Fred Hutch Cancer Center)Marc Gurwith(Vaxart (United States))William L. Heyward(Vaxart (United States))Michael Martin(Ministry of Public Health)Fritz van Griensven(Ministry of Public Health)Dale J. Hu(Centers for Disease Control and Prevention)Jordan W. Tappero(Ministry of Public Health)Kachit Choopanya(Bangkok Metropolitan Administration)Bangkok Vaccine Evaluation Group
Abstract
Despite the successful completion of this efficacy trial, the vaccine did not prevent HIV-1 infection or delay HIV-1 disease progression.
HIV Research and TreatmentHIV/AIDS drug development and treatmentHepatitis C virus researchMedicinePlaceboInternal medicineVaccine trialHIV vaccineClinical endpointImmunologyVaccine efficacyRandomized controlled trialConfidence interval
MeSH terms
Acquired Immunodeficiency SyndromeAdultDouble-Blind MethodFemaleHumansInjections, IntramuscularMaleMiddle AgedRecombinant ProteinsThailandVaccinationHIV-1HIV InfectionsHIV Envelope Protein gp120Substance Abuse, Intravenous
Citations
825
FWCI
11.23
field-weighted impact
References
43
Percentile
99%
vs. same field & year
Citations per year
Cited by
A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies
PLoS Pathogens · 2013 · 993 citations
Global trends in molecular epidemiology of HIV-1 during 2000–2007
AIDS · 2011 · 677 citations
References
Placebo‐Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV‐1 Infection
The Journal of Infectious Diseases · 2005 · 931 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.